We are pleased to share that Dewpoint has contributed an insightful article to the latest eReport on neuroscience. The article, authored by our very own Diana Mitrea, 'Leveraging the power of molecular communities' explores the groundbreaking potential of targeting biomolecular condensates for therapeutic development. Diana discusses how our AI-powered platform is used to identify novel condensate targets, validate hypotheses, and discover and optimize c-mods (condensate-modulating drugs). This approach shows promising results in addressing complex diseases such as ALS by targeting aberrant condensates and restoring cellular function. Dive into the details of our innovative research and its implications for future treatments here https://bit.ly/4bwh48G
The global prevalence of dementia is approximately 24 million, and is predicted to double every 20 years until at least 2040. Currently, no medications can cure this, though 2024 has proved to be a poignant year of developments in neuroscience, especially considering the challenges faced in previous decades. This guide, sponsored by ApconiX, showcases the potential within drug discovery. While putting this report together, it was a pleasure to hear insight from ApconiX’s Director and Co-founder, Professor Ruth Roberts, and Scientific Lead, Kimberly Rockley. In addition, a scientific article by Dewpoint Therapeutics' Associate Director for Scientific Communications Diana Mitrea on developing therapeutics targeting biomolecular condensates. Register and download this FREE e-report now. https://hubs.li/Q02DS40t0
Congratulations on this contribution! Looking forward to diving into the full article and learning more about innovations in this field.